Li, X., Peterson, Y.K., Inks, E.S., Himes, R.A., Li, J.Y., Zhang, Y.J., et al. (2018) Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. Journal of Medicinal Chemistry, 61, 2589-2603.
https://doi.org/10.1021/acs.jmedchem.8b00136

has been cited by the following article:

• TITLE: Mechanism Study of the Kidney Renal Papillary Cell Carcinoma Proliferation Inhibition and Apoptosis Induction by EZH2

  AUTHORS: Shubo Wang

  KEYWORDS: Cancer Cell, Small Molecule Inhibitor, SKRC39, KIRP, EZH2, P53

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.9 No.2, February 5, 2021

  ABSTRACT: EZH2 is an important target in a variety of tumors, but its role in KIRP (Kidney renal papillary cell carcinoma) has not yet been proven. The aim of this study was to investigate the role of EZH2 in KIRP patients. And to investigate the KIRP, we used two KIRP cell lines, SKRC39 and ACHN in this study. We used CCK8 assay and colony formation assay to study the effect of EHZ2 small molecule inhibitor EPZ6438 on cancer cell proliferation, we used Trypan Blue cell counting experiments to study the effect of EZH2 on cancer cell apoptosis, and we also used qRT-PCR to study the mechanism of EZH2 on cancer cell proliferation. The results showed that EZH2 was elevated in KIRP patients; inhibition of EZH2 could inhibit the proliferation of cancer cells and induce the apoptosis of cancer cells, which is valuable for the control of KIRP in patients. As for the mechanism, we found that inhibition of EZH2 upregulated P53 expression and thus activated this tumor suppressor gene, indicating why EHZ1 inhibits renal cancer cells.